A pilot study evaluated cytoreductive surgery combined with immune checkpoint therapy in patients with metastatic renal cell carcinoma.
Jim Kling
Advertisement
Articles by Jim Kling
A phase I study of a CAR T-cell therapy showed success in refining cell dosing and adverse event management protocols in patients with relapsed/refractory ALL.
Advertisement
Latest Updated Articles
Promising CAR T-Cell Agent for ALL Enters Phase II With Revised AE Management ProtocolPublished: June 3rd 2019 | Updated:
Safety of Immune Checkpoint Inhibitors With Nephrectomy in mRCCPublished: June 4th 2019 | Updated:
Advertisement
Advertisement
